Skip to main content

Hepatitis Be Antigen

CPT 87350
Synonyms
  • HBeAg
  • HBV
  • hepatitis B
  • hepatitis B e-antigen

Test Details

Methodology

Immunochemiluminometric assay (ICMA)

Result Turnaround Time

1 - 3 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

The HBe antigen assay, in conjunction with other serological and clinical information, can be used for the determination and management of chronic hepatitis B infection. This assay should not be used for the diagnosis of acute Hepatitis B infection.

Special Instructions

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.

Limitations

This assay has not been FDA-approved for the diagnosis of individuals with acute hepatitis B infection.

Assay performance characteristics have not been established for testing of children less than 17 years of age or pregnant women or in populations of immunocompromised or immunosuppressed patients.

This assay has not been licensed for the screening of blood, plasma, and tissue donors.

References

Abara WE, Qaseem A, Schillie S, et al. Hepatitis B Vaccination, Screening, and Likage to Care: Best Practice Advice from American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804.29159414
Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018 Jan 12;67(1):1-31.29939980
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018 Apr;67(4):1560-1599.29405329
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815

Custom Additional Information

HBe antigen becomes detectable shortly after HBsAg is detectable and is an indicator of active infection and replicating virus. The disappearance of HBeAg and the appearance of anti-HBe together with other HBV markers allow the clinician to determine a prognosis, and to follow the progression of the disease from acute to chronic or recovered status.

Specimen Requirements

Specimen

Serum or plasma

Volume

1.5 mL

Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)

Container

Gel-barrier tube or lavender-top (EDTA) tube

Collection Instructions

If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.

Stability Requirements

Temperature

Period

Room Temperature

7 days (stability provided by manufacturer or literature reference)

Refrigerated

7 days (stability provided by manufacturer or literature reference)

Frozen

1 year (stability provided by manufacturer or literature reference)

Freeze/thaw cycles

Stable x3 (stability provided by manufacturer or literature reference)

Reference Range

Negative

Storage Instructions

Room temperature

Causes for Rejection

Non-EDTA plasma specimen; heat-inactivated specimens; cord blood; cadaver specimens; or body fluids other than serum or EDTA plasma

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
006619 Hep Be Ag 13954-3 006619 Hep Be Ag 13954-3
Order Code006619
Order Code NameHep Be Ag
Order Loinc13954-3
Result Code006619
Result Code NameHep Be Ag
UofM
Result LOINC13954-3